熱門資訊> 正文

Kiora Pharmaceuticals GAAP每股收益为-0.54美元

2025-08-08 19:09

Kiora Pharmaceuticals press release (NASDAQ:KPRX): Q2 GAAP EPS of -$0.54.
Ended the quarter with $20.7 million in cash, cash equivalents and short-term investments, along with $2.4 million in collaboration receivables and $0.7 million in research incentive tax credits.
Maintained projected cash runway into late 2027, a timeframe beyond anticipated data readouts for KLARITY and ABACUS-2, with potential for further extension through achievement of partnership milestones.

More on Kiora Pharmaceuticals

Kiora Pharmaceuticals granted U.S. patent expanding protection for KIO-104 for treatment of ocular disease
Seeking Alpha’s Quant Rating on Kiora Pharmaceuticals
Historical earnings data for Kiora Pharmaceuticals
Financial information for Kiora Pharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。